NewsRoom Articles - Page 1222 of 1423

ThursdaySep 28, 2017 9:00 am

Cannabinoid Biosynthesis Poised as Potential Game-Changer in Drug Development

NetworkNewsWire Editorial Coverage: As the marijuana market continues its widespread growth, researchers remain merely at the threshold of exploring the manifold potential medical applications of cannabis. At present, more than 90 individual cannabinoid compounds have been discovered within the cannabis plant—each one potentially possessing crucial disease-fighting properties either on its own or combined with other compounds. Historically, however, it has been incredibly difficult to extract most of these compounds from the marijuana plant in adequate quantities and purities to be tested pharmaceutically. Overcoming this stumbling block in medical cannabis advancement, Vancouver-based biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)…

WednesdaySep 27, 2017 4:30 pm

Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Oramed Pharmaceuticals (NASDAQ: ORMP) engages in the technology of oral delivery solutions for drugs currently delivered via injection. Oramed's Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. The company is focused on revolutionizing the treatment of diabetes through its proprietary flagship product, ORMD-0801, an orally ingestible insulin capsule. Oramed has completed multiple phase 2 clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. Oramed is also developing ORMD-0901, an oral GLP-1 analog capsule. For more information, visit the company’s website at…

WednesdaySep 27, 2017 4:00 pm

Safeguard Scientifics, Inc. (NYSE: SFE) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Safeguard Scientifics (NYSE: SFE) provides capital and expertise to stimulate the growth of technology-driven businesses in healthcare, financial services and digital media. The company targets companies that are capitalizing on the next wave of enabling technologies with a particular focus on the Internet of Everything, enhanced security and predictive analytics. Safeguard typically deploys between $5 million and $25 million over the course of its partnership with a company, initially investing in a Series A or B Round and opportunistically in a Seed Round. Safeguard has a notable track record of fostering innovation and building market leaders that spans more than…

WednesdaySep 27, 2017 3:46 pm

EVIO, Inc. (SGBYD) Changes Name, Adopts New Ticker Symbol and Announces a Reverse Stock Split

Name change to EVIO, Inc., from Signal Bay, Inc., reflects fact that EVIO Labs division generates majority of company volume New ticker symbol of EVIO will become effective October 3, 2017, for the legalized cannabis industry’s quality control testing and ancillary advisory services company Reverse stock split is positioned to attract institutional investors to provide funding for company’s vision of becoming a leading biotechnology firm in the cannabis industry EVIO, Inc. (OTCQB: SGBYD) has changed its name from Signal Bay, Inc. and also announced a reverse stock split (http://nnw.fm/ViB3C). The life science company will also have a new ticker symbol,…

WednesdaySep 27, 2017 3:30 pm

Midatech Pharma PLC (NASDAQ: MTP) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Midatech Pharma (NASDAQ: MTP) is an international specialty pharmaceutical company focused on oncology. The company’s approach comprises of developing oncology products internally and collaborating with partners in other therapy areas. The company’s strategy also involves driving growth both organically and through strategic acquisitions. Midatech is currently engaged in the US commercial operation of marketing four cancer care supportive products and co-promoting two others. Additionally, the company supports its research and development activities through its two breakthrough drug delivery technologies; the company’s proprietary gold nanoparticles and Q-Sphera for sustained release. For more information, visit the company’s website at www.midatechpharma.com. About NetworkNewsWire…

WednesdaySep 27, 2017 3:18 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Targets Specific Diseases with its Proprietary Biotechnologies

Provisional patent application protects unique process yielding pharmaceutical grade, bio-identical cannabinoids Proprietary research allows production of synthetic cannabinoids for therapeutic use with certain diseases Early stage clinical trials are expected to begin in 2018 for a drug targeting a rare children’s skin disorder Imagine having a painful disease that causes your skin to blister at the slightest minor injury. Even just scratching an itch or accidentally rubbing against a rough object could cause peeling blisters and acute suffering. Epidermolysis bullosa, a genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States, currently has…

WednesdaySep 27, 2017 3:00 pm

Rockwell Medical, Inc. (NASDAQ: RMTI) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Rockwell Medical (NASDAQ: RMTI) is a fully-integrated biopharmaceutical company with a focus on end-stage renal disease (ESRD) and chronic kidney disease (CKD). The company provides innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Triferic, the company’s anemia drug, is FDA approved for iron replacement and maintenance of hemoglobin in hemodialysis patients. The company also has an FDA approved generic drug, Calcitriol, for treating secondary hyperparathyroidism in dialysis patients. Rockwell also manufactures high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. For more information, visit the company’s website at www.rockwellmed.com. About NetworkNewsWire NetworkNewsWire…

WednesdaySep 27, 2017 2:30 pm

Applied DNA Sciences, Inc. (NASDAQ: APDN) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Applied DNA Sciences (NASDAQ: APDN) provides molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics. The company’s proprietary DNA-based “CertainT™” platform can be used to identify, tag, test and track products to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopiable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All…

WednesdaySep 27, 2017 2:30 pm

Chanticleer Holdings, Inc. (NASDAQ: HOTR) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Chanticleer Holdings (NASDAQ: HOTR) owns, operates and franchises fast casual and full-service dining concepts in the United States and internationally. Chanticleer owns and operates and franchises restaurant brands including American Burger Company, BGR - Burgers Grilled Right, Little Big Burger, Just Fresh and Hooters. For more information, visit the company’s website at www.chanticleerholdings.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As…

WednesdaySep 27, 2017 2:00 pm

Research Frontiers Inc. (NASDAQ: REFR) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Research Frontiers (NASDAQ: REFR) develops and markets the technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device (SPD-Smart) light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, light-control film made from the chemical emulsion, the light-control panels made by laminating the film, lamination services, and electronics to power end-products incorporating the film, as well as the end-products, such as windows, skylights, and sunroofs. Its SPD-Smart light-control technology is used in multiple product applications. For more information, visit the company’s website at www.smartglass.com. About NetworkNewsWire NetworkNewsWire (NNW)…

Financial news and publishing for public and private companies

Contact us: 512.354.7000